Teva sees FY24 EPS $2.20-$2.50, consensus $2.42

Sees FY24 revenue $15.7B-$16.3B, consensus $15.57B. Sees FY24 adjusted EBITDA $4B-$4.5B. Sees FY24 capital expenditures $500M. Sees FY24 free cash flow $1.7B-$2B. Francis continued, “In 2024, we look forward to seeing continued progress across our key innovative growth drivers, while also executing on our high-value, complex generics business with new product launches, and achieving the exciting clinical milestones of our late-stage pipeline assets.”